Literature DB >> 29397409

FRAX calculated without BMD does not correctly identify Caucasian men with densitometric evidence of osteoporosis.

R C Hamdy1, E Seier2, K Whalen3, W A Clark4, K Hicks3, T B Piggee3.   

Abstract

The FRAX algorithm assesses the patient's probability of sustaining an osteoporotic fracture and can be calculated with or without densitometric data. This study seeks to determine whether in men, FRAX scores calculated without BMD, correctly identify patients with BMD-defined osteoporosis.
INTRODUCTION: The diagnosis of osteoporosis is based on densitometric data, the presence of a fragility fracture or increased fracture risk. The FRAX algorithm estimates the patient's 10-year probability of sustaining an osteoporotic fracture and can be calculated with or without BMD data. The purpose of this study is to determine whether in men, FRAX calculated without BMD, can correctly identify patients with BMD-defined osteoporosis.
METHODS: Retrospectively retrieved data from 726 consecutive Caucasian males, 50 to 70 years old referred to our Osteoporosis Center.
RESULTS: In the population studied, 11.8 and 25.3% had BMD-defined osteoporosis when female and male reference populations were used respectively. When the National Osteoporosis Foundation thresholds to initiate treatment are used, only 27% of patients with BMD-defined osteoporosis, but 4% with normal BMD reached/exceeded these thresholds. Lowering the threshold increased sensitivity, but decreased specificity.
CONCLUSIONS: Our results suggest that FRAX without BMD is not sensitive/specific enough to be used to identify Caucasian men 50 to 70 years old with BMD-defined osteoporosis.

Entities:  

Keywords:  Bone mineral density; FRAX; Management; Men; Osteoporosis

Mesh:

Year:  2018        PMID: 29397409     DOI: 10.1007/s00198-017-4368-6

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  22 in total

Review 1.  Uses and limitations of bone mineral density measurements in the management of osteoporosis.

Authors:  Ralph E Small
Journal:  MedGenMed       Date:  2005-05-09

2.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.

Authors:  C H Chesnut; S Silverman; K Andriano; H Genant; A Gimona; S Harris; D Kiel; M LeBoff; M Maricic; P Miller; C Moniz; M Peacock; P Richardson; N Watts; D Baylink
Journal:  Am J Med       Date:  2000-09       Impact factor: 4.965

3.  Importance of bone mineral density measurements in evaluating fragility bone fracture risk in Asian Indian men.

Authors:  K Kuruvilla; A M Kenny; L G Raisz; J E Kerstetter; R S Feinn; T V Rajan
Journal:  Osteoporos Int       Date:  2010-05-06       Impact factor: 4.507

4.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

5.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

Review 6.  Assessment of fracture risk.

Authors:  John A Kanis; Helena Johansson; Anders Oden; Eugene V McCloskey
Journal:  Eur J Radiol       Date:  2009-08-28       Impact factor: 3.528

7.  Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Authors:  Charles H Chesnut; Arne Skag; Claus Christiansen; Robert Recker; Jacob A Stakkestad; Arne Hoiseth; Dieter Felsenberg; Hermann Huss; Jennifer Gilbride; Ralph C Schimmer; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2004-03-29       Impact factor: 6.741

8.  Bone mineral density thresholds for pharmacological intervention to prevent fractures.

Authors:  Ethel S Siris; Ya-Ting Chen; Thomas A Abbott; Elizabeth Barrett-Connor; Paul D Miller; Lois E Wehren; Marc L Berger
Journal:  Arch Intern Med       Date:  2004-05-24

Review 9.  Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry.

Authors:  John T Schousboe; John A Shepherd; John P Bilezikian; Sanford Baim
Journal:  J Clin Densitom       Date:  2013 Oct-Dec       Impact factor: 2.617

10.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Authors:  J A Kanis; E V McCloskey; H Johansson; C Cooper; R Rizzoli; J-Y Reginster
Journal:  Osteoporos Int       Date:  2012-10-19       Impact factor: 4.507

View more
  3 in total

Review 1.  Bone health in ageing men.

Authors:  Karel David; Nick Narinx; Leen Antonio; Pieter Evenepoel; Frank Claessens; Brigitte Decallonne; Dirk Vanderschueren
Journal:  Rev Endocr Metab Disord       Date:  2022-07-16       Impact factor: 9.306

2.  FRAX score with and without bone mineral density: a comparison and factors affecting the discordance in osteoporosis treatment in Thais.

Authors:  Napassorn Teeratakulpisarn; Suranut Charoensri; Daris Theerakulpisut; Chatlert Pongchaiyakul
Journal:  Arch Osteoporos       Date:  2021-02-26       Impact factor: 2.617

3.  FRAX Calculated without BMD Resulting in a Higher Fracture Risk Than That Calculated with BMD in Women with Early Breast Cancer.

Authors:  Rizky Suganda Prawiradilaga; Victoria Gunmalm; Trine Lund-Jacobsen; Eva Wulff Helge; Charlotte Brøns; Michael Andersson; Peter Schwarz
Journal:  J Osteoporos       Date:  2018-10-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.